Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 6/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 0.80 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17522791 | 0.97 | TTR (0.94) | TTRALBARHSD17B10GAA | |
| SCHEMBL19801746 | 0.91 | TTR (0.84) | TTRALBARHSD17B10GAA | |
| Acoramidis SCHEMBL15816954 | 0.89 | TTR (1.00) | TTRALBHSD17B10GAASMN1; SMN2 | |
| SCHEMBL24953188 | 0.89 | TTR (0.83) | TTRALBHSD17B10GAASMN1; SMN2 | |
| Acoramidis SCHEMBL29350324 | 0.89 | TTR (1.00) | TTRALBHSD17B10GAASMN1; SMN2 | |
| SCHEMBL26745347 | 0.88 | TTR (0.79) | TTRALBARHSD17B10GAA | |
| Acoramidis SCHEMBL20475239 | 0.88 | TTR (0.98) | TTRALBHSD17B10GAASMN1; SMN2 | |
| Acoramidis SCHEMBL29390976 | 0.88 | TTR (0.98) | TTRALBHSD17B10GAASMN1; SMN2 | |
| SCHEMBL15816998 | 0.88 | TTR (0.81) | TTRALBHSD17B10GAASMN1; SMN2 | |
| SCHEMBL25311559 | 0.87 | TTR (0.77) | TTRALBARHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313534-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | ALTER DOMUS (US) LLC, AS COLLATERAL AGENT | 2025-10-09 | — | — | US | disclosed |
| US-20250186399-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| US-20250041276-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | ALTER DOMUS (US) LLC, AS COLLATERAL AGENT | 2025-02-06 | — | — | US | disclosed |
| US-12070449-B2 | Methods of treating TTR amyloidosis using AG10 | Eidos Therapeutics, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240239751-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | BRIDGEBIO GENE THERAPY RESEARCH, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239751-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | BRIDGEBIO GENE THERAPY RESEARCH, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239751-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | BRIDGEBIO GENE THERAPY RESEARCH, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240199577-A1 | ACORAMIDIS ANALOGS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11919865-B2 | Processes for preparing AG-10, its intermediates, and salts thereof | Eidos Therapeutics, Inc. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-12-07 | — | — | US | disclosed |
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | MAHA THERAPEUTICS, INC. | 2016-02-18 | — | — | US | disclosed |
| EP-2934514-A1 | TRANSTHYRETIN STABILIZERS AND THEIR USE FOR INHIBITING TRANSTHYRETIN AMYLOIDOSIS AND PROTEIN-PROTEIN INTERACTIONS | The Board of Trustees of The Leland Stanford Junior University (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9169214-B2 | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169214-B2 | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169214-B2 | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-10-27 | — | — | US | disclosed |
| WO-2014100227-A1 | TRANSTHYRETIN STABILIZERS AND THEIR USE FOR INHIBITING TRANSTHYRETIN AMYLOIDOSIS AND PROTEIN-PROTEIN INTERACTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100227-A1 | TRANSTHYRETIN STABILIZERS AND THEIR USE FOR INHIBITING TRANSTHYRETIN AMYLOIDOSIS AND PROTEIN-PROTEIN INTERACTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179751-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2014-06-26 | — | — | US | disclosed |
| US-20140179751-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2014-06-26 | — | — | US | disclosed |
| US-20140179751-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179751-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | TTR, PRNP, APP | TTR 1/4885ALB 6/4885AR 4223/4885 |
| US-20250041276-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | TTR, TMSB10, APOB | TTR 1/4885ALB 4/4885AR 3315/4885 |
| US-12070449-B2 | Methods of treating TTR amyloidosis using AG10 | TTR, APOB, TMSB10 | TTR 1/4885ALB 4/4885AR 3507/4885 |
| US-20250186399-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | TTR, PRNP, APP | TTR 1/4885ALB 6/4885AR 4223/4885 |
| US-20250313534-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | UGT1A10, SAMM50, AGL | TTR 109/4885ALB 43/4885AR 637/4885 |
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | TTR, PRNP, APP | TTR 1/4885ALB 6/4885AR 4223/4885 |
| US-20240239751-A1 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | UGT1A10, SAMM50, AGL | TTR 109/4885ALB 43/4885AR 637/4885 |
| US-20240199577-A1 | ACORAMIDIS ANALOGS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TNNC1, MTPN | TTR 1/4885ALB 12/4885AR 3221/4885 |
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | TTR, TTPA, SERPINA6 | TTR 1/4885ALB 4/4885AR 3715/4885 |
| US-11919865-B2 | Processes for preparing AG-10, its intermediates, and salts thereof | UGT1A10, SAMM50, AGL | TTR 109/4885ALB 43/4885AR 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.